The nonparametric bootstrapping analysis showed that the 95% CIs for ICERs were in a range of US$54,391 to US$231,475 ( US$70,894 to $37,945) for all-cause death and US$28,870 to US$122,865 ( S$37,630 to US$20,141) for hospitalized hypoglycemia from the payer perspective (healthcare sector perspective)
Meanwhile, Roche, Pfizer, AstraZeneca, Boehringer Ingelheim, and Amgen are pursuing them with different technologies such as oral small molecules, once-monthly administration, GLP-1/GIP, GLP-1/glucagon, and GIP receptor antagonism
NEED TO KNOW Serena Williams opens up to PEOPLE about feeling great after losing 34 lbs
Questions & Answers 1
It is your responsibility to ensure they have all the facts